News Abbott Laboratories Swiss Exchange

Stocks

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Delayed Swiss Exchange Other stock markets 01:36:25 17/06/26 am AEST			5-day change	1st Jan Change
71.00 ^CHF	+0.71%		-2.07%	-28.28%

13/06	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15	MT
13/06	Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026	CI

All News

Mentions Relevance

19/06	Big Claims, Little Kids: Recent SDNY Decision Highlights Risks In Advertising	AQ
13/06	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15	MT
13/06	Abbott declares 410th consecutive quarterly dividend	PR
13/06	Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026	CI
12/06	BofA Adjusts Price Target on Abbott Laboratories to $102 From $120	MT
08/06	New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers	PR
07/06	Abbott Announces Dual Glucose-Ketone Sensing Technology with Libre Duo and Libre Duo 10 Day Systems	CI
06/06	New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis	PR
05/06	Abbott Labs must face lawsuit over PediaSure children's growth claims	RE
28/05	Abbott Gets CE Mark for Glucose-Ketone Sensing Technology for Diabetes	MT
27/05	Abbott secures CE mark for dual glucose-ketone sensing technology for diabetes patients	RE
27/05	Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes	PR
27/05	ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening	PR
27/05	Abbott Highlights Cologuard And Cologuard Plus As Preferred Noninvasive Colorectal Cancer Screening Options In Updated American Cancer Society Guideline	CI
27/05	Goldman Sachs Adjusts Price Target on Abbott Laboratories to $113 From $121, Maintains Buy Rating	MT
26/05	Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026	PR
13/05	NVision announced a $55 million Series B financing round anchored by Abbott	RE
13/05	NVISION IMAGING Technologies GmbH announced that it has received $38 million in funding from b2venture AG, Playground Global, LLC, Entrée Capital Limited, Matterwave Ventures Management GmbH, Abbott Laboratories and other investors	CI
05/05	Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase	MT
30/04	Abbott Laboratories : to highlight expanding cancer diagnostic portfolio and clinical evidence at Digestive Disease Week (DDW) 2026	PU
30/04	Tranche Update on Abbott Laboratories's Equity Buyback Plan announced on October 16, 2024.	CI
29/04	Abbott Laboratories Says Ultreon 3.0 Coronary Imaging Software Receives FDA Clearance, CE Mark	MT
28/04	Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform	PR
28/04	Abbott Receives Fda Clearance for Next-Generation Ultreon 3.0 Ai-Powered Coronary Imaging Platform	CI
28/04	Abbott Laboratories Announces Board Changes	CI